TNF alpha as a therapeutic target in rheumatoid arthritis.

Rheumatoid arthritis (RA) is an autoimmune disease with inflammatory manifestations in the peripheral synovial joints, which are infiltrated by activated T cells, macrophages, and plasma cells. We have investigated the role of cytokines in RA and have proposed that tumour necrosis factor has a pivot...

Full description

Bibliographic Details
Main Authors: Feldmann, M, Brennan, F, Elliott, M, Katsikis, P, Maini, R
Format: Journal article
Language:English
Published: 1994
_version_ 1826299402555228160
author Feldmann, M
Brennan, F
Elliott, M
Katsikis, P
Maini, R
author_facet Feldmann, M
Brennan, F
Elliott, M
Katsikis, P
Maini, R
author_sort Feldmann, M
collection OXFORD
description Rheumatoid arthritis (RA) is an autoimmune disease with inflammatory manifestations in the peripheral synovial joints, which are infiltrated by activated T cells, macrophages, and plasma cells. We have investigated the role of cytokines in RA and have proposed that tumour necrosis factor has a pivotal role in the pathogenesis of this disease. This chapter describes those studies, which led to the first clinical trial in RA patients using a chimeric anti TNF alpha antibody. In addition to pro-inflammatory cytokine production, at sites of inflammation such as the RA synovial joint, there is also evidence for homeostatic immunoregulatory mechanisms which include the production of cytokine inhibitors, such as soluble TNF-R and the IL-1 receptor antagonist, and cytokines with immunoregulatory properties like IL-10. The evidence for these inhibitors in RA is presented, and the relevance of this homeostatic mechanism in relation to chronic inflammatory diseases is discussed.
first_indexed 2024-03-07T05:01:24Z
format Journal article
id oxford-uuid:d8663090-1027-41d3-93f6-367191b0ea71
institution University of Oxford
language English
last_indexed 2024-03-07T05:01:24Z
publishDate 1994
record_format dspace
spelling oxford-uuid:d8663090-1027-41d3-93f6-367191b0ea712022-03-27T08:48:18ZTNF alpha as a therapeutic target in rheumatoid arthritis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d8663090-1027-41d3-93f6-367191b0ea71EnglishSymplectic Elements at Oxford1994Feldmann, MBrennan, FElliott, MKatsikis, PMaini, RRheumatoid arthritis (RA) is an autoimmune disease with inflammatory manifestations in the peripheral synovial joints, which are infiltrated by activated T cells, macrophages, and plasma cells. We have investigated the role of cytokines in RA and have proposed that tumour necrosis factor has a pivotal role in the pathogenesis of this disease. This chapter describes those studies, which led to the first clinical trial in RA patients using a chimeric anti TNF alpha antibody. In addition to pro-inflammatory cytokine production, at sites of inflammation such as the RA synovial joint, there is also evidence for homeostatic immunoregulatory mechanisms which include the production of cytokine inhibitors, such as soluble TNF-R and the IL-1 receptor antagonist, and cytokines with immunoregulatory properties like IL-10. The evidence for these inhibitors in RA is presented, and the relevance of this homeostatic mechanism in relation to chronic inflammatory diseases is discussed.
spellingShingle Feldmann, M
Brennan, F
Elliott, M
Katsikis, P
Maini, R
TNF alpha as a therapeutic target in rheumatoid arthritis.
title TNF alpha as a therapeutic target in rheumatoid arthritis.
title_full TNF alpha as a therapeutic target in rheumatoid arthritis.
title_fullStr TNF alpha as a therapeutic target in rheumatoid arthritis.
title_full_unstemmed TNF alpha as a therapeutic target in rheumatoid arthritis.
title_short TNF alpha as a therapeutic target in rheumatoid arthritis.
title_sort tnf alpha as a therapeutic target in rheumatoid arthritis
work_keys_str_mv AT feldmannm tnfalphaasatherapeutictargetinrheumatoidarthritis
AT brennanf tnfalphaasatherapeutictargetinrheumatoidarthritis
AT elliottm tnfalphaasatherapeutictargetinrheumatoidarthritis
AT katsikisp tnfalphaasatherapeutictargetinrheumatoidarthritis
AT mainir tnfalphaasatherapeutictargetinrheumatoidarthritis